Navigation Links
Forest and Cypress Announce FDA Approval of Savella(TM) for the Management of Fibromyalgia
Date:1/14/2009

oncurrent improvement to multiple validated measures, including pain (visual analog scale), patient global assessment (patient global impression of change), and physical function (Short Form-36 Physical Component Summary).

The efficacy of Savella was established in two US pivotal Phase III clinical trials involving 2,084 treated patients (1,460 Savella; 624 placebo), which showed that Savella demonstrated clinically significant improvements compared to placebo in treating fibromyalgia. The first study was 6 months in duration and the second study was 3 months in duration.

In both studies, a greater proportion of patients in the Savella treatment arms (100 mg/day and 200 mg/day) as compared with placebo treatment, at 3 months, experienced at least a 30% reduction in pain from baseline and also rated themselves as "very much improved" or "much improved" based on the patient global assessment. In addition, a greater proportion of patients treated with Savella as compared with placebo treatment met the criteria for a treatment response as measured by concurrent improvements in pain, physical function, and patient global assessment. In both studies, some patients who rated themselves as globally "much" or "very much" improved experienced a decrease in pain as early as week 1 of treatment with a stable dose of Savella that persisted throughout these studies.

The clinical development program demonstrated that Savella was safe and generally well tolerated. The most frequently occurring adverse reaction was nausea. Other common adverse reactions reported in these clinical trials were constipation, hot flush, hyperhidrosis, vomiting, palpitations, heart rate increased, dry mouth and hypertension. The majority of adverse reactions reported were mild to moderate in nature.

About Savella

Savella is a dual-reuptake inhibitor that preferentially blocks the reuptake of norepinephrine with high
'/>"/>

SOURCE Forest Laboratories, Inc.; Cypress Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Third Quarter Earnings
2. Forest Laboratories Announces Executive Exercised Stock Options With Intent to Hold Shares
3. Forest Laboratories Responds To Unsolicited Mini-Tender Offer
4. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
5. Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians
6. Wake Forest researchers say popular fish contains potentially dangerous fatty acid combination
7. Lake Forest, CA: SpeechPhone Launches Handsfree Driving Solution Just in Time to Comply with New Handsfree Driving Laws
8. Wake Forest Class Taps Recordant for Web-Based Search and Playback of Course Materials
9. Cleaner Air May Threaten Amazon Rainforest
10. Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment
11. Metrologic and Wake Forest University Baptist Medical Center Sponsored Healthcare Educational Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 (HealthDay News) -- New research warns parents that ... lives at risk. Nearly half of teen drivers killed in ... were at least 11 years old and often lacked important safety ... Eighty-two percent of teen drivers killed in crashes were in cars ... to 10 years old, 31 percent were in cars 11 to ...
(Date:12/19/2014)... News) -- Injectable drug users who also use cocaine ... of other substance users, a new study finds. ... risk of suicide attempt and completed suicide," Didier Jutras-Aswad, ... in a university news release. "However, there are many ... who among substance users were actually more likely to ...
(Date:12/19/2014)... Raleigh, NC (PRWEB) December 19, 2014 Surviving ... asbestos and EPA information indicates that these pipes can leach ... to go to the full story on the Surviving ... to the erosion of natural asbestos deposits, decaying water mains ... in drinking water. , To protect consumers from ...
(Date:12/19/2014)... Kan. (PRWEB) December 19, 2014 B. ... exclusively to healthcare providers, has been retained to lead ... Johnson Memorial Hospital in Franklin, Ind. The top executive ... has recently placed more than 900 healthcare executives into ... county-owned, full service hospital providing care to the residents ...
(Date:12/19/2014)... Pain Free Living a leader in the ... new Superior magnetic necklace using ion neodymium ... neodymium magnets for the fastest pain relief in a ... Magnetics brand for the fastest relief by using 5200 ... using Superior Magnetic Jewelry at fairs and festivals” explained ...
Breaking Medicine News(10 mins):Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:New Superior Magnetic Necklace Relieves Migraine Headache 2
... Only program that facilitates creation of a 3D model ... N.Y., Feb. 18 /PRNewswire/ -- ... technology that enables orthodontists to create an accurate 3D ... single impression. Combining advanced CT scanning technology with GAC,s ...
... Outgoing Cabinet Head and Former Utah Governor to Provide ... ReformORLANDO, Fla., Feb. 18 ConnextionsHealth announced today that ... Services under President George W. Bush from 2005 to ... address the World Health Care Congress Leadership Summit on ...
... N.C. A widely used blood pressure medication may ... after radiation treatment, according to a newly published study ... The findings offer the hope of an improved ... rat model, the study drew on a hypothesis from ...
... journal Nature Genetics have for the first ... attack and coronary heart disease. In one of the ... the Myocardial Infarction Genetics Consortium identified nine precise genes ... of them newly discovered; the investigators said that these ...
... to Providing High Quality Services to the CommunityLOS ... ("Avanti") is pleased to announce that it has ... Gardena ("MHG") and East Los Angeles Doctors Hospital ... been providing quality acute and sub-acute healthcare services ...
... -- Medical travel company Companion Global ... and U.S. employer groups now have additional options ... care while remaining closer to home.Companion Global Healthcare ... the CIMA Hospitals in Hermosillo, Mexico, and Monterrey, ...
Cached Medicine News:Health News:OrthoPlex 3D Digital Modeling Solution Introduced by Dentsply GAC 2Health News:Former Health & Human Services Secretary Michael Leavitt to Address Health Plan Member Retention Summit 2Health News:Former Health & Human Services Secretary Michael Leavitt to Address Health Plan Member Retention Summit 3Health News:Blood pressure compound may benefit brain tumor patients 2Health News:Blood pressure compound may benefit brain tumor patients 3Health News:New genomic markers associated with risk of heart disease and early heart attack 2Health News:Avanti Health System Acquires Two Los Angeles Hospitals 2Health News:Avanti Health System Acquires Two Los Angeles Hospitals 3Health News:Avanti Health System Acquires Two Los Angeles Hospitals 4Health News:Companion Global Healthcare Expands Service to Include Hospitals in Mexico 2
(Date:12/19/2014)... market has witnessed robust development with the growth pace keeping ... starter. In 2012, the size of China ... proportion worldwide soaring to 16.3%. It is projected that ... growth rate by around 20% in the upcoming years and ... billion. An integrated membrane industrial system has taken ...
(Date:12/17/2014)... , Dec. 17, 2014  Strategic Health Services, ... software solutions, today announced a strategic agreement with QualCare, ... New Jersey regional marketplace.  This agreement ... the health and wellness solutions QualCare brings to its ... the surrounding region. QualCare plans cover ...
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... 2012 Reportlinker.com announces that a new ... catalogue:   ... Devices http://www.reportlinker.com/p0799254/Pricing-and-Reimbursement-Strategies-for-Medical-Devices.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Facility ... medical devices being purchased within public healthcare ...
... Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel ... the TREAT-NMD Advisory Committee on Therapeutics (TACT) has ... dystrophy (DMD), and believes the compound has potential ... global network dedicated to expediting the delivery of ...
Cached Medicine Technology:Pricing and Reimbursement Strategies for Medical Devices 2Pricing and Reimbursement Strategies for Medical Devices 3Pricing and Reimbursement Strategies for Medical Devices 4Halo Therapeutics Reports Favorable Independent Review of Lead Drug Candidate HT-100 2Halo Therapeutics Reports Favorable Independent Review of Lead Drug Candidate HT-100 3